All the below link and tweets are in English.
取り急ぎ以下貼っておきます。
California Vol.25 (corporations: Amgen)
ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
Since 2011, Amgen has doubled its global presence and, with the addition of Amgen K.K., that now includes Japan. In 2019 alone, we invested more than $4 billion in global research & development to serve more patients. Press release: https://t.co/uBT5FT4fnw 2/2 pic.twitter.com/wstcLnvnnz
— Amgen (@Amgen) April 1, 2020
We’re pleased to introduce Amgen K.K., a wholly-owned affiliate in Japan which will enable Amgen to build a strong presence in the country moving forward. Amgen K.K. will focus on bringing our full global pipeline to Japanese patients. Press release: https://t.co/uBT5FT4fnw 1/2 pic.twitter.com/fkqXj6g6Tm
— Amgen (@Amgen) April 1, 2020
#Amgen’s New #Osteoporosis Treatment Receives First Worldwide Approval in Japan https://t.co/JooD4GUxgK @UCB_News
— Amgen (@Amgen) January 8, 2019
#ICYMI, #Amgen’s medicine for R/R ALL has received marketing authorization in Japan. Learn more: https://t.co/UMrQByPqtD
— Amgen (@Amgen) September 26, 2018
#Amgen receives approval for our R/R ALL medicine in Japan. Learn more: https://t.co/UMrQByPqtD
— Amgen (@Amgen) September 25, 2018
Applications for the #AmgenScholars Program in Europe, Japan & the U.S. are open now: https://t.co/uVtH11AW1w pic.twitter.com/rt3JekGqix
— Amgen (@Amgen) December 13, 2017
The #AmgenScholars Japan Symposium was a global gathering of passionate young #scientists. Learn more: https://t.co/CvuLhtGpQF
— Amgen (@Amgen) January 10, 2017
#Amgen & @UCB_news announce submission of marketing application in Japan for osteoporosis treatment https://t.co/Z27LnrD17x
— Amgen (@Amgen) December 20, 2016
#Amgen submits marketing application in Japan http://t.co/DSa8puB2Ms
— Amgen (@Amgen) March 20, 2015
#Amgen presents new detailed cholesterol data from Japan study at #ACC15 http://t.co/A8Crv951Em
— Amgen (@Amgen) March 14, 2015
Japan’s #biosimilar guidelines aim toward #quality, #safety and #efficacy. Full article: http://t.co/xzDMFOgozN via @GaBIOnline_
— Amgen (@Amgen) September 27, 2013
As the Japan #AmgenScholars Program enters its fifth year, Steve Sugino, Vice President of @Amgen, caught up with its Directors, Dr. Ichiro Sakuma and Dr. Fuyuki Ishikawa about their experience with the program. https://t.co/2opFJZxRUb
— Amgen Foundation (@AmgenFoundation) April 10, 2019
@Amgen establishes a wholly-owned affiliate in Japan by announcing the completion of 49% share buyout in a 7-year-old joint venture with Astellas Pharma Inc.#Japan #Healthcare #GeneOnlinehttps://t.co/rfMMQHKd9e
— GeneOnline (@GeneOnlineNews) April 1, 2020
#Pharma with '#AI friendly' executives will prosper: US, Germany, and Japan-based companies lead the pack, says @DK_Analytics report // @DeepTech_VC
Read: https://t.co/Ra1FDwHAXE@Boehringer @GSK @LillyPad @Evotec @pfizer @Amgen @BayerPharma @Roche @Novartis @bmsnews @Merck pic.twitter.com/df32pzpwpr
— Outsourcing-Pharma (@OutsourcPharma) July 8, 2019
What are the key challenges for #osteoporosis patients in #Japan and how are these affecting their daily lives? Our persona portrait explores the issue. #bonehealthAsia https://t.co/6I7R6gsnr3 (Commissioned By @Amgen) pic.twitter.com/XSzyeHQBpH
— The Economist Intelligence Unit (@TheEIU) March 28, 2019
In Japan, #cardiovascular diseases (CVDs) levy US$24.3bn in direct and indirect costs on individuals, their households and the public finances. What can be done to reduce CVDs costs? Download report> https://t.co/GvIrb2yynd (Via @Amgen) #HearthealthAsia pic.twitter.com/b0syBOLu9W
— The Economist Intelligence Unit (@TheEIU) December 21, 2018
Amgen and UCB's Evenity approved in Japan for #osteoporosis https://t.co/GvzSmOIQv5 #pharma @Amgen @ucb_news pic.twitter.com/gcs0QJ4SJi
— Pharmafocus (@Pharmafocus) January 9, 2019
BLINCYTO® (Blinatumomab) Approved in Japan for the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia @Amgen https://t.co/TxsNrf7oZ1
— Hematopoiesis News (@Hema_News) September 28, 2018
Japan to cut drug prices, @bmsinfo @OnoPharmaOpdivo (nivolumab) & @Amgen Repatha (evolocumab) into the spotlight https://t.co/3xzxFn3muY
— ilS (@ilsintelligence) September 19, 2016
@Amgen's #Repatha wins first PCSK9 OK in #Japan https://t.co/EeEEqDTq40 @FiercePharma #hypercholesterolemia #cholesterol #cardiovascular
— Plexus Ventures (@PlexusVentures) January 25, 2016
@Amgen signs autoimmune pact with Japan's Teijin – Read more via @PharmaTimes here: http://t.co/OlktgphSz9 #autoimmune #Japan #pharma
— Plexus Ventures (@PlexusVentures) August 1, 2013
#Amgen announces approval of Repatha® (evolocumab) in Japan https://t.co/uOn5L1sab3
— Amgen (@Amgen) January 22, 2016
#Amgen and Astellas Announce Japan Alliance http://t.co/oRgJwzycLz
— Amgen (@Amgen) May 29, 2013
Amgen Repurchases Astellas’ Stakes in Amgen Astellas JV to Strengthen its Footprints in Japan @Amgen @AstellasUS https://t.co/9RLS4NdZg2 pic.twitter.com/5eHR6tMorO
— PharmaShots – Incisive news in 3 shots (@Pharmashot) April 1, 2020
@Amgen establishes a wholly-owned affiliate in Japan by announcing the completion of 49% share buyout in a 7-year-old joint venture with Astellas Pharma Inc.#Japan #Healthcare #GeneOnlinehttps://t.co/rfMMQHKd9e
— GeneOnline (@GeneOnlineNews) April 1, 2020
Amgen & Astellas Enter Into Japan Alliance http://t.co/345v46RfBp @amgen @AstellasUS
— Asian Scientist Magazine (@asianscientist) June 7, 2013
#Amgen and @DaiichiSankyoJP announce agreement to commercialize #biosimilars in Japan. https://t.co/bVDl6FJaet
— Amgen (@Amgen) July 14, 2016
#collaboration between @Amgen and @EUdaiichisankyo to #commercialize nine #biosimilars in #Japan.
For more: https://t.co/R2fyWqM00i— Roots Analysis (@RootsAnalysis) July 18, 2016
@Amgen & @DaiichiSankyo announce agreement to commercialize #biosimilars in #Japan https://t.co/D3xmqmRiJo @WorldPharmaNews #biosim #pharma
— Plexus Ventures (@PlexusVentures) July 14, 2016
.@Amgen agrees deal to commercialise biosimilars in Japan with @EUdaiichisankyo https://t.co/O7cdaYN3Ml
— Pharmafocus (@Pharmafocus) July 14, 2016
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan https://t.co/KsanOqAcmi [h/t @Amgen]
— Endpoints News (@endpts) July 14, 2016
.@Amgen partners with @DaiichiSankyoJP to market biosimilars in Japan https://t.co/fieuGDAidm via @biopharmadive pic.twitter.com/hsWno7fsfd
— NewYork Pharma Forum (@NYPharmaForum) July 23, 2016
.@Amgen partners with @DaiichiSankyoJP to market biosimilars in Japan https://t.co/UpKRfQvYGV via @biopharmadive pic.twitter.com/6H9mg6Ou5y
— NewYork Pharma Forum (@NYPharmaForum) July 22, 2016
AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study | @AbbVieUS @Amgen @TakedaOncology @WHO #cambridge #massachusetts #thousandoaks #california #covid19 #biotech https://t.co/HAJfTVcTOR
— Pharm2Market (@pharm2market) August 6, 2020
Rival drugmakers launch joint trial of drugs for #COVID19 https://t.co/LcRNln9jaK @gulf_news #coronavirus @AbbVie @Amgen @Takeda
— Gulf News Business (@GulfNewsBiz) August 3, 2020
Our heads of R&D, Takeda's Andy Plump and @Amgen's David Reese, published a @statnews opinion article about the efforts of the COVID R&D Alliance and the power of adaptive trials. Learn how a global network can accelerate the fight against #COVID19 https://t.co/x5gYQT8nVj pic.twitter.com/lXs0YOkkVK
— Takeda (@TakedaPharma) July 23, 2020
Affymax banks $50M milestone on ESA drug approval http://t.co/T5PeWE5y $AFFY $AMGN @Takeda @Amgen
— FierceBiotech (@FierceBiotech) April 10, 2012
#Peptide_Based_Cancer_Therapeutics Market Size Worth $17.18 Billion By 2027
Read More : https://t.co/k5GadYh4D3
major market participants :@AstraZeneca @Allergan @Pfizer @Takeda @Amgen,@JNJNews#peptidetherapeutics #healthcare pic.twitter.com/8LF46fwnPm
— karishma mulani (@karishmamulani5) July 28, 2020
.@TakedaPharma to return molecules/ products for Japan to @Amgen https://t.co/14hGlLgKu6
— Pharmafocus (@Pharmafocus) June 27, 2016
参考．上記linkに無いもの
“The world now recognizes that we need innovation to get out from under the crush of this pandemic.”
Amgen CEO Bob Bradway spoke with @FT's @HannahKuchler about navigating #COVID19 now and preparing for a post-COVID world. #FTUSPharma $AMGN
— Amgen (@Amgen) October 6, 2020
If you’re a provider, visit our updated #COVID19 & cardiovascular resource page which also includes a link to important resources in the @HFSA COVID-19 resource hub to learn more.
Details in the link below.
— Amgen (@Amgen) October 1, 2020
Amgen's Michelle Carillo from our advocacy relations team will join for this discussion. Registration details in link below. #COVID19 https://t.co/wLqtf8dr8A
— Amgen (@Amgen) September 29, 2020
Moderated by MassBio CEO @BobCoughlin, Michelle Carrillo @Amgen, Dr. Meghan Mooradian @MassGeneralNews & Kirsten Sloan @ACSCAN join us now for a discussion on how #COVID19 has impacted cancer care & the path to diagnosis & treatment. Thank you, @Amgen for sponsoring this event! pic.twitter.com/mG5Lb9Hd8f
— MassBio (@MassBio) October 1, 2020
Dr. Steven Galson of @Amgen discussing #COVID19 and the promise of genetic sequencing. A great conversation on how science is meeting this critical moment for our world. #CALeg pic.twitter.com/rn7kDoqWap
— California Biotech (@CABiotech) May 28, 2020
.@PhRMA companies and CMTA members @LillyPad, @TakedaPharma, @pfizer, @JNJInnovation, @Amgen, @Novartis part of coordinated intl. research response for #COVID19 treatments and vaccines. #MakingCA #ProtectingUS https://t.co/K81hC2aHPe
— California Manufacturers & Technology Assn. (@cmta) April 21, 2020
Wonderful news from CLSA members @Amgen and @LillyPad!
The spirit of life sciences collaboration embodies our ability to defeat this pandemic! #innovation > #COVID19 https://t.co/NnfbMCq62H
— California Life Sciences Association (CLSA) (@CALifeSciences) September 17, 2020
In the fight against the pandemic, @LillyPad announced a partnership with @Amgen to #manufacture a new #COVID19 treatment! #CreatorsRespond https://t.co/ihMQVEWabZ
— Friends of Manufacturing (@FriendsofMFG) September 17, 2020
Lilly and Amgen announce manufacturing collaboration for COVID-19 antibody therapies. @WorldPharmaNews @LillyPad @Amgen #COVID19 #antibodies #LYCoV555 #lifesciences #pharma https://t.co/h2TiFilMDl pic.twitter.com/bUbAsek5xs
— Greybridge (@GreybridgeRoles) September 22, 2020
With rising numbers of #diabetic and #chronicdisease #patients, the #wearable #injectors market is growing for ease of #drugadministration. (https://t.co/dNV34tAMEh)
.
.
.#injection #syringe #drugdelivery #medicine #Amgen #BD #Insulet #Medtronic #COVID19 #TBRC #GlobalMarketModel pic.twitter.com/jExYhkjBf7— TBRC (@tbrc_info) September 22, 2020
Amgen adapts to pandemic with #Prolia home infusion; #Otezla as COVID-19 therapy @Amgen #covid19 #earnings@MichaelHGibney reports https://t.co/lsTmjgdaDz pic.twitter.com/psknF2KIok
— Market Intelligence: Healthcare (@SPGMIHealthcare) July 29, 2020
Discover what it's like to be an outbreak response team member in Amgen #BiotechExperience's new virtual curriculum module that explores the #COVID19 pandemic, Responding to a Mystery Illness.
Read all about it: https://t.co/kecQFvdMA4 pic.twitter.com/TqquQDmqdT— ABE Program Office (@ABEProgOffice) April 27, 2020
Working with @AdaptiveBiotech, @Amgen is working on a drug to treat #COVID19. #CreatorsRespond https://t.co/BKYN0PgIk6
— The NAM (@ShopFloorNAM) April 3, 2020
First Patients Registered in I-SPY COVID Trial https://t.co/4wzf17dWb6 via @GMP news #AbbVie #Amgen #ClinicalTrials #Covid19 #Takeda #GMPNews
— GMPnews.Net (@GMPnewsNet) August 4, 2020
Tune in as @American_Heart CEO @NancyatHeart and @Amgen CEO Bob Bradway discuss #COVID19 rapid response efforts, especially for heart disease and stroke patients who are at higher risk & rightfully concerned. https://t.co/rAOt9UJFD4
— American Heart News (@HeartNews) May 19, 2020
Thank you @Amgen Canada for your donations, supplies, and expertise to our Canadian communities to help fight against #COVID19. #CanadaResilient Learn more > https://t.co/70V9BlXh29 pic.twitter.com/Mo34pp6FPg
— Mississauga Business (@MississaugaEDO) May 6, 2020
At shareholder meetings this spring investors asked #BigPharma to commit to freeze prices on key drugs in light of the #COVID19 pandemic. Tomorrow the industry is set to again raise prices. CEO Bradway of @Amgen – will you commit? https://t.co/Aratl9g4iU
— ICCR (@ICCRonline) June 30, 2020
#NasdaqListed @Amgen marks a major milestone with a note of gratitude to #healthcare workers.
How they're stepping up to address the #COVID19 pandemic: https://t.co/PBb1vBMhAd https://t.co/0pWytEJcHp pic.twitter.com/R9aolBQRET
— Nasdaq (@Nasdaq) April 8, 2020
Boehringer Ingelheim-backed COVID researchers identify new antibodies to fight the virus | @boehringerus @UniCologneNY @DZIF_ @lillypad @Regeneron @Amgen @AstraZeneca #immunesystem #covid19 #biotech #research https://t.co/T8Y9zaIVX0
— Pharm2Market (@pharm2market) July 11, 2020
